Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1791563

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1791563

Cell and Gene Therapy Clinical Trial Services

PUBLISHED:
PAGES: 154 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Cell and Gene Therapy Clinical Trial Services Market to Reach US$28.9 Billion by 2030

The global market for Cell and Gene Therapy Clinical Trial Services estimated at US$11.7 Billion in the year 2024, is expected to reach US$28.9 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$15.1 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 15.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 15.3% CAGR

The Cell and Gene Therapy Clinical Trial Services market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 15.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.2% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.8% CAGR.

Global Cell and Gene Therapy Clinical Trial Services Market - Key Trends & Drivers Summarized

Why Is the Demand for Cell and Gene Therapy Clinical Trial Services Increasing?

The demand for cell and gene therapy clinical trial services is increasing due to the growing number of innovative therapies entering the development pipeline, the rise of personalized medicine, and the expanding regulatory support for advanced therapeutic products. Cell and gene therapies have shown significant potential in treating previously untreatable conditions, including rare genetic disorders, cancers, and neurodegenerative diseases. As pharmaceutical and biotech companies continue investing in regenerative medicine, the need for specialized clinical trial services has grown exponentially.

Advancements in genetic engineering, CRISPR-based technologies, and autologous and allogeneic cell therapies have further accelerated research and development efforts in this field. With a rise in clinical trials targeting rare diseases and oncology, contract research organizations and specialized trial service providers are playing a critical role in ensuring regulatory compliance, patient recruitment, and trial execution. Additionally, global regulatory agencies such as the FDA and EMA are introducing streamlined approval pathways for cell and gene therapies, increasing the demand for clinical trial expertise to navigate the complex regulatory landscape.

How Are Technological Advancements Improving Cell and Gene Therapy Clinical Trials?

Technological innovations in clinical trial design, real-time monitoring, and patient data analytics are revolutionizing the execution of cell and gene therapy studies. One of the most significant advancements is the use of artificial intelligence and machine learning to optimize patient recruitment and predictive modeling for therapy outcomes. AI-driven trial design helps identify suitable candidates, improve trial efficiency, and reduce time-to-market for breakthrough therapies.

Another major breakthrough is the integration of decentralized clinical trials, which enable remote patient monitoring and reduce the logistical challenges associated with traditional study designs. Wearable biosensors, telemedicine platforms, and electronic patient-reported outcomes are making trials more patient-centric, ensuring better compliance and data collection. Additionally, advancements in cryopreservation and logistics for cell-based therapies are enhancing the ability to conduct multi-site and global trials. With increasing automation in laboratory processes and bioinformatics tools for genomic analysis, cell and gene therapy trials are becoming more precise, scalable, and efficient.

Which Market Trends Are Driving Growth in the Cell and Gene Therapy Clinical Trial Services Industry?

The increasing number of clinical trials focused on rare diseases and oncology is one of the most influential trends shaping the cell and gene therapy clinical trial services market. Many of these therapies target small patient populations, requiring specialized recruitment strategies and trial designs tailored to complex treatment protocols. The expansion of regenerative medicine and immunotherapy-based treatments has also led to a growing need for customized trial services that address the unique challenges of cell-based interventions.

Another key trend influencing market growth is the rise of global collaborations between pharmaceutical companies, research institutions, and contract research organizations. As cell and gene therapy trials require specialized facilities, skilled personnel, and advanced manufacturing capabilities, companies are increasingly outsourcing clinical trial management to experienced service providers. Additionally, regulatory harmonization across different regions is facilitating faster approvals, allowing companies to conduct multi-center trials more efficiently. The increasing role of real-world evidence in therapy assessment is also shaping clinical trial methodologies, integrating long-term patient outcomes into approval and reimbursement strategies.

What Are the Key Growth Drivers Shaping the Future of the Cell and Gene Therapy Clinical Trial Services Market?

The growth in the cell and gene therapy clinical trial services market is driven by several factors, including increased investment in regenerative medicine, the rise of advanced biomanufacturing techniques, and evolving regulatory frameworks supporting novel therapies. One of the primary growth drivers is the significant funding from both public and private sectors into cell and gene therapy research, with governments and venture capital firms heavily investing in next-generation treatments.

Another crucial driver shaping the market is the expansion of clinical trial infrastructure, including specialized research centers and manufacturing hubs dedicated to advanced therapies. As the demand for personalized treatments increases, trial service providers are focusing on adaptive trial designs and precision medicine approaches to improve therapy efficacy and patient outcomes. Additionally, the increasing acceptance of decentralized and hybrid trial models is enabling wider patient participation and reducing trial costs. As the field of cell and gene therapy continues to evolve, clinical trial services will remain essential in bringing transformative treatments to market, addressing complex diseases, and advancing the future of precision medicine.

SCOPE OF STUDY:

The report analyzes the Cell and Gene Therapy Clinical Trial Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Indication (Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication, Immunology and Inflammation Indication, Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Charles River Laboratories
  • Clinipace
  • Covance Inc.
  • ICON plc
  • IQVIA Biotech
  • KCR
  • Labcorp Drug Development
  • Linical Co., Ltd.
  • Medpace
  • Novotech
  • Parexel International
  • Pivotal Clinical Research
  • PPD (Thermo Fisher Scientific)
  • PRA Health Sciences
  • Premier Research
  • Syneos Health
  • Synteract
  • Veristat
  • Worldwide Clinical Trials
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP29863

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cell and Gene Therapy Clinical Trial Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surging Pipeline of Advanced Therapies Throws the Spotlight on Specialized Cell and Gene Therapy (CGT) Clinical Trial Services
    • Increasing Complexity of CGT Trial Protocols Propels Demand for Niche CRO Expertise and Infrastructure
    • Growth in Orphan and Rare Disease Drug Development Expands the Addressable Market for CGT Clinical Trial Providers
    • Expansion of Personalized and Autologous Therapies Strengthens the Business Case for Highly Customized Trial Designs
    • High Manufacturing and Supply Chain Sensitivities Spur Need for Integrated CGT Logistics and Trial Coordination Services
    • Globalization of CGT Trials Fuels Demand for Multiregional Site Management and Regulatory Navigation Support
    • Emergence of Decentralized and Hybrid Trial Models Enhances Patient Accessibility and Enrollment for CGT Studies
    • Advanced Biomarker and Companion Diagnostic Development Drives Demand for Integrated Bioanalytical Services
    • Innovations in Digital Health Tools and eSource Data Collection Streamline Complex CGT Trial Operations
    • Specialized Patient Recruitment Strategies Become Critical in Ultra-Niche CGT Trial Populations
    • Increasing Role of Real-World Evidence and Long-Term Follow-Up Requirements Extends Scope of CGT Trial Services
    • Cell Banking, Cryopreservation, and Chain-of-Custody Protocols Drive Infrastructure Investment in Trial Support Services
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cell and Gene Therapy Clinical Trial Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Hematology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Hematology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Musculoskeletal Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Musculoskeletal Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Endocrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Metabolic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Genetic Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Genetic Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Infectious Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Infectious Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for CNS Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for CNS Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Cardiology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Cardiology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Ophthalmology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Ophthalmology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Immunology & Inflammation Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Immunology & Inflammation Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 36: USA Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • JAPAN
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • CHINA
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • EUROPE
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • FRANCE
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • GERMANY
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • UNITED KINGDOM
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 78: Asia-Pacific Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Asia-Pacific 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 82: Rest of World Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of World 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 84: Rest of World Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of World 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!